The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
Open accessAbstract
Because macrophages have been implicated as major players in the mechanism of action of rituximab, we have investigated the factors that modulate their tumor cell killing potential. Human macrophages, differentiated in vitro from peripheral blood monocytes, were used in binding and phagocytosis assays using B-chronic lymphocytic leukemia or lymphoma target cells opsonized with rituximab. Phagocytosis was maximal at 0.1 μg/ml rituximab and was not significantly affected by CD20 expression levels or by CD16A polymorphism at position 158 (Val/Phe). The role of FcγRs was demonstrated by complete inhibition of phagocytosis by excess human Igs. Because macrophages can be differentiated to M1- or M2-type cells with either GM-CSF or M-CSF, respectively, and can be classically activated by proinflammatory stimuli (IFN-γ/LPS) or undergo alternative activation with cytokines such as IL-4 or IL-10, we have analyzed the effect of these different polarization programs on the phagocytosis mediated by rituximab. Macrophages differentiated in presence of M-CSF showed a 2- to 3-fold greater phagocytic capacity compared with GM-CSF-induced cells. Furthermore, addition of IL-10 significantly increased, whereas IL-4 decreased phagocytosis by both M-CSF- and GM-CSF-differentiated macrophages. LPS/IFN-γ had little effect. Expression of CD16, CD32, and CD64 in different macrophage populations correlated with phagocytic activity. Interestingly, several B lymphoma cell lines were observed to secrete 400-1300 pg/ml IL-10 in vitro, and coculture of human macrophages with lymphoma conditioned medium increased significantly their phagocytic capacity. Our data suggest that cytokines secreted by lymphoma cells can favor alternate activation of macrophages with a high phagocytic capacity toward rituximab-opsonized targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Self-citationAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Martinez, F. O., Gordon, S., Locati, M., & Mantovani, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7303 · Cited by 2,125
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.003 · Cited by 1,451
Self-citation
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
Sousa de Almeida, M., Susnik, E., Drasler, B., Taladriz-Blanco, P., Petri-Fink, A., & Rothen-Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,079
Modulators of microglial activation and polarization after intracerebral haemorrhage
Lan, X., Han, X., Li, Q., Yang, Q.-W., & Wang, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.69 · Cited by 915
Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain
Colton, C. A. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9164-4 · Cited by 877
Zhou, D., Huang, C., Lin, Z., Zhan, S., Kong, L., Fang, C., & Li, J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2013.11.004 · Cited by 778
Glioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., & Heimberger, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq082 · Cited by 691
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Comparison of polarization properties of human adult microglia and blood‐derived macrophages
Durafourt, B. A., Moore, C. S., Zammit, D. A., Johnson, T. A., Zaguia, F., Guiot, M., Bar‐Or, A., & Antel, J. P. (2012) · Glia · doi:10.1002/glia.22298 · Cited by 477
Myers, K. V., Amend, S. R., & Pienta, K. J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1022-2 · Cited by 470
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
Roles of microglia in brain development, tissue maintenance and repair
Michell-Robinson, M. A., Touil, H., Healy, L. M., Owen, D. R., Durafourt, B. A., Bar-Or, A., Antel, J. P., & Moore, C. S. (2015) · Brain · doi:10.1093/brain/awv066 · Cited by 425
Role and mechanisms of cytokines in the secondary brain injury after intracerebral hemorrhage
Zhu, H., Wang, Z., Yu, J., Yang, X., He, F., Liu, Z., Che, F., Chen, X., Ren, H., Hong, M., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.03.003 · Cited by 318
Polarization dictates iron handling by inflammatory and alternatively activated macrophages
Corna, G., Campana, L., Pignatti, E., Castiglioni, A., Tagliafico, E., Bosurgi, L., Campanella, A., Brunelli, S., Manfredi, A. A., Apostoli, P., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.023879 · Cited by 304
“M2 macrophages satisfy these requirements: they are professional scavengers of senescent and apoptotic cells.(31,32) Furthermore we found that they express high levels of membrane molecules involved in iron internalization, such as TfR1 and the CD163 hemoglobin/haptoglobin receptor, and low levels of FtH.”
BackgroundLiu, M., O’Connor, R. S., Trefely, S., Graham, K., Snyder, N. W., & Beatty, G. L. (2019) · Nature Immunology · doi:10.1038/s41590-018-0292-y · Cited by 294
Macrophages are critical effectors of antibody therapies for cancer
Weiskopf, K., & Weissman, I. L. (2015) · mAbs · doi:10.1080/19420862.2015.1011450 · Cited by 292
The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions
Zhang, T., Song, X., Xu, L., Ma, J., Zhang, Y., Gong, W., Zhang, Y., Zhou, X., Wang, Z., Wang, Y., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2160-x · Cited by 290
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Rey-Giraud, F., Hafner, M., & Ries, C. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042656 · Cited by 257
Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402891 · Cited by 195
“diated by activated macrophages can kill tumor cells (14).”
BackgroundIDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148
Self-citationA novel real time imaging platform to quantify macrophage phagocytosis
Kapellos, T. S., Taylor, L., Lee, H., Cowley, S. A., James, W. S., Iqbal, A. J., & Greaves, D. R. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.011 · Cited by 148
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
“M2 macrophages are efficient in phagocytosis of rituximab-opsonized B cells (14), but we question the relevance of this FcgR-mediated process for solid tumors like colorectal carcinoma.”
BackgroundDelidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
Zeka, B., Hastermann, M., Kaufmann, N., Schanda, K., Pende, M., Misu, T., Rommer, P., Fujihara, K., Nakashima, I., Dahle, C., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0355-y · Cited by 65
The multi-faceted potential of CD38 antibody targeting in multiple myeloma
Shallis, R. M., Terry, C. M., & Lim, S. H. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1990-2 · Cited by 20
Metadata
- Authors
- Leidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M., Palumbo, G. A., Introna, M., & Golay, J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-01
- Volume
- 182
- Issue
- 7
- Pages
- 4415-4422
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1947298690
- Cited by
- 272
- References
- 45
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.